Market Overview

Gene Therapy for Sickle-Cell Diseases| a Drug Pipeline Analysis Report 2018| Technavio

Share:

Technavio has announced their latest pipeline analysis report on gene
therapy for sickle-cell diseases
. The report includes a detailed
analysis of the pipeline molecules under investigation within the
defined data collection period for gene therapy for sickle-cell diseases.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180725005688/en/

Technavio has published a new report on the drug development pipeline for gene therapy for sickle-ce ...

Technavio has published a new report on the drug development pipeline for gene therapy for sickle-cell diseases, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Sickle-cell diseases: Market overview

Sickle-cell diseases are a group of blood disorders caused by an
abnormality in the hemoglobin in red blood cells. Sickle-cell diseases
are inherited from parents. The patients inherit on copy of mutated
hemoglobin gene from each parent in the chromosome 11. The people with
one abnormal copy of the hemoglobin gene are called carriers, and they
do not show the traits of disease or develop the anemia. People with two
copies of the hemoglobin gene are at high risk of developing the
disease. The disease can be cured to a small extent by bone marrow cell
transplantation. Sickle-cell anemia constitutes a major part of
sickle-cell diseases (almost 80% of sickle-cell diseases). Sickle-cell
diseases can lead to severe complications such as stroke, chronic pain,
pulmonary hypertension, and osteomyelitis.

According to a senior market research analyst at Technavio, "Sickle-cell
diseases are race and geography-specific indications. The disease is
more common in the Sub-Saharan regions, India, and the Middle-Eastern
countries compared with other parts of the world."

Gene therapy for sickle-cell diseases:
Segmentation analysis

This drug pipeline analysis report segments the sickle-cell diseases
market based on therapies employed (monotherapy), RoA (intravenous),
therapeutic modality (gene), targets (CD34, and β-globin), MoA (gene
therapy), geographical segmentation (US and France) and recruitment
status (active, not recruiting, not applicable, and recruiting). It
provides an in-depth analysis of the prominent factors influencing the
market, including drivers, opportunities, trends, and industry-specific
challenges.

Based on MoA, around 80% of the molecules that are being investigated
for the treatment of sickle-cell diseases are gene therapy.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View Comments and Join the Discussion!